arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PACB
$1.18 ▲ +0.01 (+1.29%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $360.9M
Dividend Yield
Revenue Growth 0.1%
Op. Margin -22.5%
ROIC -361.2%
FCF / Share $-0.16
Trailing P/E
Price / Book 154.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.18M
— +0.1%
Net Income Profit after all expenses
$-8.28M
↑ +98.1%
Operating Margin Operating profit as % of sales
-22.5%
↑ +77.8% 0th
FCF / Share Free cash flow per share
$-0.16
↓ -2.0%
Long-Term Debt Long-term obligations
$896.84M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
15
Cash Quality
29

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters